View Post

Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour eFrom: The collective results of the MINDACT and TAILORx trials provided a better directive in terms of whether or not to give endocrine therapy alone or in combination with chemotherapy for patients with node-negative, early-stage hormone receptor (HR)–positive, HER2-negative breast cancer, said Mariana Chavez Mac Gregor, MD, MSc. “In patients who have early-stage HR-positive, HER2-negative disease, …